Kynam Capital Management, L.P. 13F annual report
Kynam Capital Management, L.P. is an investment fund managing more than $899 billion ran by Jared Keller. There are currently 21 companies in Mr. Keller’s portfolio. The largest investments include Natera Inc and Syndax Pharmaceuticals Inc, together worth $318 billion.
$899 billion Assets Under Management (AUM)
As of 7th August 2024, Kynam Capital Management, L.P.’s top holding is 2,000,000 shares of Natera Inc currently worth over $183 billion and making up 20.3% of the portfolio value.
Relative to the number of outstanding shares of Natera Inc, Kynam Capital Management, L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 5,660,000 shares of Syndax Pharmaceuticals Inc worth $135 billion, whose value fell 9.6% in the past six months.
The third-largest holding is Celldex Therapeutics worth $122 billion and the next is Vera Therapeutics Inc worth $65.8 billion, with 1,526,787 shares owned.
Currently, Kynam Capital Management, L.P.'s portfolio is worth at least $899 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Kynam Capital Management, L.P.
The Kynam Capital Management, L.P. office and employees reside in Princeton, New Jersey. According to the last 13-F report filed with the SEC, Jared Keller serves as the COO at Kynam Capital Management, L.P..
Recent trades
In the most recent 13F filing, Kynam Capital Management, L.P. revealed that it had opened a new position in
Ironwood Pharmaceuticals Inc and bought 1,625,000 shares worth $14.2 billion.
This means they effectively own approximately 0.1% of the company.
Ironwood Pharmaceuticals Inc makes up
1.9%
of the fund's Health Care sector allocation and has decreased its share price by 55.2% in the past year.
The investment fund also strengthened its position in Cogent Biosciences by buying
2,645,234 additional shares.
This makes their stake in Cogent Biosciences total 8,500,000 shares worth $57.1 billion.
Cogent Biosciences dropped 28.8% in the past year.
On the other hand, there are companies that Kynam Capital Management, L.P. is getting rid of from its portfolio.
Kynam Capital Management, L.P. closed its position in Immunogen on 14th August 2024.
It sold the previously owned 1,422,503 shares for $42.2 billion.
Jared Keller also disclosed a decreased stake in Natera Inc by 0.2%.
This leaves the value of the investment at $183 billion and 2,000,000 shares.
One of the average hedge funds
The two most similar investment funds to Kynam Capital Management, L.P. are Seven Eight Capital, L.P. and Td Capital Management. They manage $955 billion and $955 billion respectively.
Jared Keller investment strategy
Kynam Capital Management, L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 83.3% of
the total portfolio value.
The fund focuses on investments in the United States as
52.4% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.55 billion.
The complete list of Kynam Capital Management, L.P. trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Natera Inc |
16.67%
2,000,000
|
$182,920,000,000 | 20.35% |
| Syndax Pharmaceuticals Inc |
No change
5,660,000
|
$134,708,000,000 | 14.99% |
| Celldex Therapeutics Inc. |
3.52%
2,900,000
|
$121,713,000,000 | 13.54% |
| Vera Therapeutics Inc |
58.17%
1,526,787
|
$65,835,055,000 | 7.32% |
| Cogent Biosciences, Inc. |
45.18%
8,500,000
|
$57,120,000,000 | 6.35% |
| Dynavax Technologies Corp. |
179.97%
4,239,780
|
$52,615,670,000 | 5.85% |
| Vaxcyte, Inc. |
25.68%
745,000
|
$50,890,950,000 | 5.66% |
| Immunogen, Inc. |
Closed
1,422,503
|
$42,177,214,000 | |
| Morphosys AG |
Closed
4,234,685
|
$41,923,382,000 | |
| Liquidia Corp |
16.68%
2,248,324
|
$33,162,779,000 | 3.69% |
| Biocryst Pharmaceuticals Inc. |
41.90%
6,527,491
|
$33,159,654,000 | 3.69% |
| Protagonist Therapeutics Inc |
42.93%
1,144,242
|
$33,102,921,000 | 3.68% |
| 2seventy Bio Inc |
No change
5,953,825
|
$31,852,964,000 | 3.54% |
| Wave Life Sciences Ltd. |
No change
3,932,082
|
$24,260,946,000 | 2.70% |
| Travere Therapeutics Inc |
No change
2,000,000
|
$15,420,000,000 | 1.72% |
| Ironwood Pharmaceuticals Inc |
Opened
1,625,000
|
$14,153,750,000 | 1.57% |
| Sutro Biopharma Inc |
No change
2,001,727
|
$11,309,758,000 | 1.26% |
| Amarin Corp Plc |
No change
12,022,957
|
$10,710,050,000 | 1.19% |
| Tyra Biosciences Inc |
51.44%
515,190
|
$8,449,116,000 | 0.94% |
| Burning Rock Biotech Ltd |
10.89%
9,640,914
|
$7,019,549,000 | 0.78% |
| Caribou Biosciences Inc |
No change
1,068,527
|
$5,492,229,000 | 0.61% |
| Centessa Pharmaceuticals Plc |
Closed
442,704
|
$3,523,924,000 | |
| Acelyrin Inc |
66.97%
396,379
|
$2,675,558,000 | 0.30% |
| Viridian Therapeutics Inc |
77.98%
133,877
|
$2,344,186,000 | 0.26% |
| No transactions found | |||
| Showing first 500 out of 24 holdings | |||
Hedge funds similar to Kynam Capital Management, L.P.
- Sound View Wealth Advisors
- Harbor Investment Advisory
- Charter Oak Capital Management
- Globeflex Capital L P
- Rational Advisors
- Murchinson
- Td Capital Management
- Seven Eight Capital, L.P.
- Keel Point
- Anchor Investment Management
- Schwerin Boyle Capital Management Inc
- Marks Wealth Management, Inc
- Kopernik Global Investors
- Tompkins Financial Corp